A Phase 4 interventional study of Ertapenem in Gastric Varix, Sepsis and Liver Cirrhoses, sponsored by Taipei Veterans General Hospital, Taiwan. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-10-28.
Sponsored by Taipei Veterans General Hospital, Taiwan · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Esophageal and Gastric Varices with a site in Taiwan — 3 open to participants now, 3 under way, none of them phase 3. Esophageal and Gastric Varices · Taiwan.
Among the 11 studies in Esophageal and Gastric Varices with a site in Taiwan, this one is the 3rd largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2017, is one of 7 in phase 4, and was the 6th registered.
150 studies on the registry are indexed under Esophageal and Gastric Varices; 39 are open to participants now.
Browse Esophageal and Gastric Varices studies →3 of the 11 studies in Esophageal and Gastric Varices with a site in Taiwan are open now. Recruiting first, the newest first:
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 18–90
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20–90
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 20 Esophageal and Gastric Varices studies recruiting now, 13 (65%) set no upper age limit and 1 (5%) stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 20 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 110 across 96 interventional studies indexed under Esophageal and Gastric Varices.
Median enrollment 120 across the 10 interventional studies, 140 across the 1 observational. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 5 most frequent:
Taipei Veterans General Hospital, Taiwan is the lead sponsor of 338 studies on the registry; 74 are open to participants now.
Taipei Veterans General Hospital, Taiwan has 6 studies filed under Esophageal and Gastric Varices — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Esophageal and Gastric Varices with a site in Taiwan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
We design a randomized trial to clarify the necessity of antibiotic prophylaxis for the patients chronic liver disease with gastric varices treated by elective GVO.
Gastric varices is not uncommon is patients with chronic liver diseases including liver cirrhosis and hepatocellular carcinoma. Occurrence of gastric varices (GV) rupture is less often than esophageal varices (EV) but it is characteristic of higher rebleeding rate and mortality and represents an even tougher problem than EV hemorrhage. Endoscopic treatment is an alternative in the management of GV bleeding. Injection sclerotherapy has been applied to arrest GV hemorrhage but it is associated with a high rebleeding rate (50\~90%) and thus is regarded as only a temporary hemostatic measure. The advantage of endoscopic variceal ligation is not suggested due to its high rebleeding rate more than 50%. Endoscopic injection of N-butyl-2-cyanoacrylate, a so-called "tissue glue",is more effective to treat GV bleeding because of more than 90% successful rate to arrest acute bleeding. The theoretical advantages of tissue glue derives from its unique ability to plug the varix lumen immediately after injection into varices. However, its rebleeding rate is still high around 30\~40% and has potential treatment-related morbidity such as embolic and septic complications. Regardless of these disadvantage, the guideline form major international society and Bavenoconsensus recommend GVO as the first treatment of choice for GV bleeding. Therefore how to prevent the potential complications and reduce rebleedingremains an important and practical issue.
With regarding to potential septic infections and rebleeding, the effects of impaired leukocyte function in cirrhotic patients and reduced immunity and increased gut permeability of severe hemorrhagic patients were contributory. In these immunocompromised hosts, when invasive procedure such as GVO is deployed for these patients, the septic complication become un-neglectable, We found (Gastrointest Endosc 2001) more than 1/3 patients undergoing GVO may complicated with bacteremia. Although most of these bacteremia were self-limited, 2% died of sepsis. Moreover, lots of cases were reported due to persistent and recurrent bacterial infections caused by GVO. Antibiotic prophylaxis has been suggested as an integral part for the management of cirrhotic patients with acute varicealbleeding by major international society and Baveno consensus. However, there is no evidence to suggest antibiotic prophylaxis for the patients treated by elective GVO. Therefore we design a randomized trial to clarify the necessity of antibiotic prophylaxis for the patients chronic liver disease with gastric varices treated by elective GVO.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participate will be acepted ertapenem(1g) iv before endoscopic cyanoacrylate injection obliteration
Drug: Ertapenem
Participate will not be acepted ertapenem(1g) iv before endoscopic cyanoacrylate injection obliteration
inject from iv drip before endoscopic cyanoacrylateinjection obliteration
Also known as: Invanz
Prevetion of sepsis
If Antibiotic Prophylaxis can reduce sepsis in Patients Undergoing GVO
Time frame: 3 years
Rebleeding rate
If Antibiotic Prophylaxis can reduce GV rebleeding rate
Time frame: 3 years
Pevention of Refractory bacterial infection
If Antibiotic Prophylaxis can reduce infection rate in Patients Undergoing GVO
Time frame: 3 years
Mortality
If Antibiotic Prophylaxis can decrease mortality in Patients Undergoing GVO
Time frame: 3 years
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2017 (actual). Primary completion is estimated for Dec 2030, 167 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ertapenem
Esophageal and Gastric Varices →
Taipei Veterans General Hospital, Taiwan →